GW&K Investment Management LLC Sells 17,849 Shares of Jazz Pharmaceuticals PLC $JAZZ

GW&K Investment Management LLC cut its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 3.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 454,712 shares of the specialty pharmaceutical company’s stock after selling 17,849 shares during the period. GW&K Investment Management LLC owned about 0.75% of Jazz Pharmaceuticals worth $59,931,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. EverSource Wealth Advisors LLC grew its position in Jazz Pharmaceuticals by 9.0% in the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 81 shares in the last quarter. Tectonic Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 1.5% in the 3rd quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock valued at $742,000 after purchasing an additional 82 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in shares of Jazz Pharmaceuticals by 0.6% in the 2nd quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock valued at $1,651,000 after purchasing an additional 90 shares during the last quarter. Fairbanks Capital Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 0.4% in the 3rd quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock worth $3,298,000 after purchasing an additional 94 shares during the period. Finally, Blue Trust Inc. increased its position in shares of Jazz Pharmaceuticals by 3.5% during the 3rd quarter. Blue Trust Inc. now owns 3,261 shares of the specialty pharmaceutical company’s stock valued at $430,000 after purchasing an additional 109 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,117 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $190.91, for a total transaction of $213,246.47. Following the transaction, the chief accounting officer owned 9,235 shares in the company, valued at approximately $1,763,053.85. This trade represents a 10.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Neena M. Patil sold 55,600 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $191.56, for a total value of $10,650,736.00. Following the completion of the sale, the executive vice president owned 56,862 shares of the company’s stock, valued at $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 73,626 shares of company stock worth $13,979,198 over the last three months. Company insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on JAZZ shares. Wall Street Zen upgraded Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. TD Cowen reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. Bank of America raised their target price on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Finally, Royal Bank Of Canada increased their price objective on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $214.57.

Jazz Pharmaceuticals Trading Up 1.1%

NASDAQ JAZZ opened at $188.69 on Thursday. The stock has a market cap of $11.62 billion, a PE ratio of -31.61, a PEG ratio of 0.37 and a beta of 0.22. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $198.00. The company’s 50-day moving average price is $170.69 and its 200-day moving average price is $153.18. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.49 by $0.15. The company had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The firm’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period in the previous year, the company earned $6.51 EPS. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.